Cybertronica Obscura Episode 3: Cyberschlock
Web series which looks at unusual science fiction movies that deal with #39;the future, #39; robots, computers, artificial intelligence, virtual reality, clones, nanotechnology, cybernetics, dystopias and related subjects.From:SternwiseViews:1 0ratingsTime:55:50More inEducation
Visit link:
Morgellons and Nanotechnology Jan Smith
The September 17, 2007 interview cont #39;d from Rense.com Playlist is here for full interview http://www.youtube.com Links: http://www.morgellonsexposed.com rense.com Stay tuned for more.... to be cont #39;d FAIR USE NOTICE: This site contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available in an effort to advance understanding of environmental, political, human rights, economic, democracy, scientific, and social justice issues, etc. We believe this constitutes a #39;fair use #39; of any such copyrighted material as provided for in section 107 of the US Copyright Law. In accordance with Title 17 USC Section 107, the material on this site is distributed without profit to those who have expressed a prior interest in receiving the included information for research and educational purposes. For more information go to:www.law.cornell.edu If you wish to use copyrighted material from this site for purposes of your own that go beyond #39;fair use #39;, you must obtain permission from the copyright owner.From:NOLIESJUSTTRUTHMEViews:0 0ratingsTime:14:58More inNonprofits Activism
More:
Nanomotoring: Syuzanna Harutyunyan at TEDxHanzeUniversity
Syuzanna is currently Assistant Professor in Chemistry at the University of Groningen. Before joining the University of Groningen she carried out research in Armenia, Russia, Poland, and Belgium. Much of her work focuses on studies towards the chemical origin of life, methods for organic chemistry and nanotechnology. She was part of the team that constructed the tiniest ever electrically driven car, which consists of a single molecule. This made it to the cover of Nature magazine (issue of 10 November 2011). http://www.sr-harutyunyan.com In thespirit of ideas worth spreading, TEDx is a program of local, self-organized events that bring people together to share a TED-like experience. At a TEDx event, TEDTalks video and live speakers combine to spark deep discussion and connection in a small group. These local, self-organized events are branded TEDx, where x = independently organized TED event. The TED Conference provides general guidance for the TEDx program, but individual TEDx events are self-organized.* (*Subject to certain rules and regulations)From:TEDxTalksViews:4 1ratingsTime:10:32More inNonprofits Activism
Continued here:
Nanomotoring: Syuzanna Harutyunyan at TEDxHanzeUniversity - Video
Presentation- iValue: The Biological Pacemaker 3929
Columbia University is developing a biological pacemaker for human use, offering a cure, rather than the palliation provided by electronic pacemakers, for heart arrhythmia. It uses encapsulated stem cells transfected with the pacemaking gene, which is a path-breaking approach to the treatment of disease. The presenting organization has assembled an intellectual property portfolio of a dozen essential patents and know-how on related nanotechnology; a consortium of top US and EU scientists/clinicians including access to clinical trial facilities; government grants from an EU country; and executives with US Food and Drug Administration and European regulatory experience. Its approach is highly capital efficient and applies the concept of open innovation. Presented by: C. Willem Houck, MBA CEO, i-Value UAB and Managing Director, i-Value LLCFrom:FasterCuresViews:3 0ratingsTime:26:35More inNonprofits Activism
View post:
FameLab Egypt 2012 - Samer Mohammed - Nanotechnology
Samer Mohammed Essam talked about "Nanotechnology" in FameLab Egypt Final Competition 2012.From:FameLabEgyptViews:0 0ratingsTime:02:03More inScience Technology
Read the original:
FameLab Egypt 2012 - Samer Mohammed - Nanotechnology - Video
The Canadian Press - ONLINE EDITION
By: Waka Tsunoda, The Associated Press
3/12/2012 10:00 AM | Comments: 0
"Nano" (Putnam), by Robin Cook
Ever since his debut as a medical thriller writer more than 30 years ago, Robin Cook, M.D., has used everything from organ transplants to alien viruses as the subject of his novels. In his latest, "Nano," he tackles nanotechnology.
It is an excellent choice, because public interest is high in this young science. Nanotechnology allows scientists to manipulate materials at the molecular level.
As the protagonist, the author brings back Pia Grazdani, who uncovered a murder disguised as a laboratory accident in Cook's last novel, "Death Benefit." She was a medical student then. Now, she is a researcher at Nano LLC, a nanotechnology research company in Boulder, Colo.
Despite unwelcome attention from the company's founder-CEO, who is obsessed with her Italian-Albanian beauty, Pia is happy enough in her new life. Then, a troubling incident occurs, and everything changes.
While out jogging, she finds a Chinese man lying on the road, seemingly in cardiac arrest. She rushes him to a local hospital, but before he can be treated, Pia's company supervisor arrives with armed guards and two official-looking Chinese men and forcibly takes custody of the patient. Pia is ordered to forget about the entire episode.
The order has just the opposite effect. She vows to find out what all these Chinese characters have to do with Nano, and what is going on in the company's high-security complex surrounded by barbed-wire fences.
View original post here:
Review: Medical thriller about nanotechnology is 1 of Robin Cook's best
FARMINGTON, Conn., Dec. 3, 2012 /PRNewswire-iReach/ -- As a technology capable of bringing closer to reality futuristic visions of intelligent device capabilities and technology-embedded environments, Nanotechnology is poised to reign supreme in diverse industries ranging from manufacturing, military, space exploration, electronics, entertainment to healthcare. The technology has already touched and improved virtually every area of modern life. From construction, consumer goods to transportation, incremental improvements in nanoscale capabilities have brightened the functionalities of materials and devices in general.
(Photo: http://photos.prnewswire.com/prnh/20121203/CG23030)
Global Information Inc (GII) highlights two significant reports on the global nanotechnology and carbon nanotubes markets from our premium market research partner Global Industry Analysts, Inc.
Nanotechnology
The global market for nanotechnology based products is projected to reach $3.3 trillion by 2018. Increasing production of nanomaterials, and rapid commercialization of nanotechnologies-enabled products are expected to drive robust opportunities for nanotechnology industry in the upcoming years. The significant drop in prices of a broad gamut of nanotechnology based products and materials such as nanoclays and silver-based nano-additives among others will especially help broaden their applications in wide spectrum of industries, thus boosting the market. Today, silver-based nano-additives find increased use in food, clothing and white goods applications. Growing penetration of nanotechnology based products in relatively niche application markets such as cosmetics, sporting goods, textiles, and environment protection also augurs well for the future of this market. Growing number of production facilities, and increasing collaboration among research institutes, universities and private sector players are also helping drive advancements in the industry. Most of the nanotechnology based products are gradually progressing from research laboratories to manufacturing process, which bodes well for the market.
Key players profiled in the report include Advanced Diamond Technologies, Inc., Advanced Nano Products Co., Limited, Altair Nanotechnologies Inc., Arrowhead Research Corporation, Bruker Corporation, Catalytic Materials, LLC, Chemat Technology Inc., eSpin Technologies, Inc., Elitech Group, Genefluidics, Inc., Hanwha Nanotech Corporation, Hybrid Plastics, Hyperion Catalysis International, Inc., Integran Technologies, Inc., Intrinsiq Materials Limited (IML), Life Technologies Corportation, Luxtera, Inc., NANOCYL S.A., NanoGram Corporation, Nanoledge, Nano Materials Ltd., Nanosys, Inc., QuantumSphere, Inc., Raymor Industries, Inc., Rogue Valley Microdevices, Inc., Shenzhen Nanotech Port Co., Ltd., SouthWest NanoTechnologies, Inc., Starpharma Holdings, Teledyne Scientific & Imaging, LLC, and Unidym, Inc., among others.
An Executive Summary for this report and free sample pages from the full document are available at http://www.giiresearch.com/report/go138620-nanotechnology.html
Carbon Nanotubes
Widely touted as the miracle material of the modern 21st century and rightly so given its remarkable and incredible electronic, thermal, and structural properties, carbon nanotubes have and will continue to remain key building blocks of technological revolution in the future. The global market for carbon nanotubes is projected to reach $1.49 billion by the year 2018. Asia-Pacific represents the largest and fastest growing market worldwide. SWCNTs are forecast to witness rapid compounded growth of approximately 14% over the analysis period. Electronics represents the fastest growing end-use application flaunting the potential to wax at a projected CAGR of 10% over the analysis period.
Leading players in the carbon nanotubes market include Arkema SA, Bayer MaterialScience AG, Catalyx Nanotech Inc., Hanwha Nanotech Corporation, Hyperion Catalysis International Inc., Nanocyl S.A., Raymor Industries Inc., Rosseter Holdings Ltd., Shenzhen Nanotech Port Co. Ltd., Showa Denko K.K, SouthWest NanoTechnologies Inc., Sun Nanotech Co. Ltd., Thomas Swan & Co. Ltd., and Unidym Inc.
Originally posted here:
Global Market for Nanotechnology to Reach $3.3 Trillion by 2018
clip 2012 12 02 19;00;19
Moores Law and Future Computing TrendsFrom:josh radfordViews:0 0ratingsTime:01:44More inPeople Blogs
Read the original here:
Newswise Researchers in the Nutritional Immunology and Molecular Medicine Laboratory at Virginia Bioinformatics Institute have discovered how a common diarrhea-causing bacterium sends the bodys natural defenses into overdrive, actually intensifying illness while fighting infection.
The discovery, recently published in PLOS One, may lead to new drug treatments for Clostridium difficile, a common germ in health care-associated infections often referred to as C. diff. It has been linked to the death of 14,000 Americans annually, according to the Centers for Disease Control and Prevention.
Researchers with the Center for Modeling Immunity to Enteric Pathogens at Virginia Tech applied computational and mathematical modeling in combination with RNA-sequencing and mouse studies to understand an important regulatory pathway during Clostridium difficile infection.
"We have found that tissue damage and disease severity in C. difficile infection is associated with a disruption of the peroxisome proliferator-activated receptor gamma (PPAR) pathway," said Josep Bassaganya-Riera, a professor of immunology, director of the Nutritional Immunology and Molecular Medicine Laboratory and the principal investigator with the Center for Modeling Immunity to Enteric Pathogens.
The human intestine must peacefully coexist with trillions of beneficial bacteria while swiftly responding to pathogens such as C. difficile. Sometimes the immune system will go into overdrive when responding to pathogens, causing more damage in an attempt to clear the infection.
Scientists studying mice bowels found the PPAR pathway keeps the immune response in check, allowing the body to heal while the immune cells that fight infection do their work in a controlled manner. When PPAR was absent or inactive, disease was more rampant and colonic lesions from C. difficile were much worse.
In addition, researchers found the protective mechanism can be activated and the severity of the C. difficile infection can be reduced by using an existing diabetes drug. More studies will be needed before the drug can be tested against C. difficile.
"This research demonstrates that the integration of powerful computer simulations of host responses with immunology experimentation not only contributes to a better understanding of the immunoregulatory processes in the gut mucosa during C. difficile infection, but it also advances the discovery of broad-based therapeutic targets in the host for infectious diseases," said Raquel Hontecillas, an assistant professor of immunology at Virginia Tech, co-director of the Nutritional Immunology and Molecular Medicine Laboratory and leader of the immunology component of the Center for Modeling Immunity to Enteric Pathogens.
The study builds on previous work from the Nutritional Immunology and Molecular Medicine Laboratory, which shows that PPAR is critical to reducing disease caused by enteric pathogens and regulating autoimmune diseases such as inflammatory bowel disease.
"With continued research, new drugs targeting this pathway will be developed that will have fewer side effects and greater efficacy than those currently on the market," Bassaganya-Riera said.
Read the original here:
Public release date: 30-Nov-2012 [ | E-mail | Share ]
Contact: Tiffany Trent ttrent@vt.edu 540-231-6822 Virginia Tech
Researchers in the Nutritional Immunology and Molecular Medicine Laboratory at Virginia Bioinformatics Institute have discovered how a common diarrhea-causing bacterium sends the body's natural defenses into overdrive, actually intensifying illness while fighting infection.
The discovery, recently published in PLOS One, may lead to new drug treatments for Clostridium difficile, a common germ in health care-associated infections often referred to as C. diff. It has been linked to the death of 14,000 Americans annually, according to the Centers for Disease Control and Prevention.
Researchers with the Center for Modeling Immunity to Enteric Pathogens at Virginia Tech applied computational and mathematical modeling in combination with RNA-sequencing and mouse studies to understand an important regulatory pathway during Clostridium difficile infection.
"We have found that tissue damage and disease severity in C. difficile infection is associated with a disruption of the peroxisome proliferator-activated receptor gamma (PPAR) pathway," said Josep Bassaganya-Riera, a professor of immunology, director of the Nutritional Immunology and Molecular Medicine Laboratory and the principal investigator with the Center for Modeling Immunity to Enteric Pathogens.
The human intestine must peacefully coexist with trillions of beneficial bacteria while swiftly responding to pathogens such as C. difficile. Sometimes the immune system will go into overdrive when responding to pathogens, causing more damage in an attempt to clear the infection.
Scientists studying mice bowels found the PPARy pathway keeps the immune response in check, allowing the body to heal while the immune cells that fight infection do their work in a controlled manner. When PPARy was absent or inactive, disease was more rampant and colonic lesions from C. difficile were much worse.
In addition, researchers found the protective mechanism can be activated and the severity of the C. difficile infection can be reduced by using an existing diabetes drug. More studies will be needed before the drug can be tested against C. difficile.
"This research demonstrates that the integration of powerful computer simulations of host responses with immunology experimentation not only contributes to a better understanding of the immunoregulatory processes in the gut mucosa during C. difficile infection, but it also advances the discovery of broad-based therapeutic targets in the host for infectious diseases," said Raquel Hontecillas, an assistant professor of immunology at Virginia Tech, co-director of the Nutritional Immunology and Molecular Medicine Laboratory and leader of the immunology component of the Center for Modeling Immunity to Enteric Pathogens.
The rest is here:
More than 1 BILLION users have uploaded more than 219 BILLION photos on Facebook. That figure is set to increase further with Facebook's new photo syncing feature. The new mobile photo syncing feature allows users to automatically upload photo from mobile phone to Facebook. All uploaded photos remain private until users share them with their friends. Facebook offers up to 2GB of free space for ...
Continued here:
Facebook Photo Syncing For Mobile Seems Neat (But I Won't Use It)
Multiple Civilian Benefits of Satellites: The Example of Health
Dr. Antonio Gell, MD, MEDES (French institute of Space medicine) addressed the Conference of the Schiller Institute on Sunday Nov 25, 2012. His presentation was titled "Multiple Civilian Benefits of Satellites: The Example of Health".From:laroucheyouthViews:0 0ratingsTime:43:37More inNews Politics
See more here:
Multiple Civilian Benefits of Satellites: The Example of Health - Video
James Hughes Reflections on Progress and the Real Future
This video of the teaching session with James Hughes begins with discussion of his TEDx talk http://www.youtube.com and then goes on to consider his Singularity 1 on 1 interview http://www.singularityweblog.com Just when you thought you would never hear a clear enunciation of the future comes the crystal clear statement by James Hughes at the end of this video about the reality of the future we face and where unemployment, post-scarcity and abundance fit into it. From the November 29th, 2012 teaching session in the Technology and Future of Medicine course LABMP 590 http://www.singularitycourse.com at the University of Alberta in Edmonton Canada. Copyright 2012 Transpath Inc.From:KimSolezViews:0 0ratingsTime:48:17More inScience Technology
Go here to see the original:
James Hughes Reflections on Progress and the Real Future - Video
acpbilling Steve Schnayer
Automatic Claims Processing inc., 15 Years Business Manager for a number of Multi-Specialty Groups, Southwestern Medical Group (Multi-Specialty of 6-7 providers including in-house laboratory and radiology) , Signature Medical Group (2-3 providers which includes Internal Medicine and Endocrinology) , eClincalworks EHR user .From:Charlie AnthonyViews:0 0ratingsTime:01:32More inScience Technology
The rest is here:
acpbilling Dr David
Automatic Claims Processing inc., is a medical billing services company in Southern California focused on helping providers get paid accurately and on time. Board Certified Sports/Family Medicine Doctor,Beverly Hills and Culver City Offices. Amazing Charts EHR user,10 Years client of ACP BillingFrom:Charlie AnthonyViews:0 0ratingsTime:00:50More inScience Technology
See the article here:
The show: A few more than 500 people took over the Charline McCombs Empire Theatre on Saturday night for a pair of Nashville-based bands, headliners Old Crow Medicine Show and openers Chuck Mead & His Grassy Knoll Boys. The crowd made enough noise, and had enough fun, for 1,000. Which raises the question: Why have promoters waited so long to book Old Crow Medicine Show in the 210 area code?
Old Crow, a slick-picking, sharp-singing, string-driven sextet with the energy and collective personality of a room full of rock bands, didnt waste any time hitting their stride with Carry Me Back to Virginia, the title track of the latest CD, and Alabama High-Test. The band was fronted by almost everyone in the crew at one time or another in the 90-minute, 25-song set. But fiddler, harmonica player, singer, etc. Ketch Secor did most of the master of ceremonies heavy lifting, making plenty of San Antonio references (vatos, fruit cups and H-E-B), making sure everyone in the house knew guitarist, banjo picker, singer and accordionist Critter Fuqua is from San Antonio, and making sure there were no dull moments.
While a breakneck fusion of mountain music, bluegrass and jug band offerings is Old Crows stock-in-trade, the band sings beautifully and spiced the Empire set with ballads, murder and otherwise, including Take 'em Away, My Good Gal and Aint It Enough.
But, for Old Crow and their fans, theres no substitute for the uptempo tunes such as Humdinger, Raise a Ruckus, Mississippi Saturday Night and Tear It Down. When Old Crow Medicine show launched into Wagon Wheel, penned with Bob Dylan, the ovation and singing along were enough to shake the Empires chairs.
Value added: For Old Crows encore, they brought Mead and the Grassy Knoll Boys onstage for Country Gal then upped the ante with a special guest, San Antonio rock n roll pioneer and conjunto ace Jesse Chucho Perales. Both Secor and Fuqua took bajo sexto lessons from Perales, and Fuqua played gigs with Perales on Main Plaza. The mass band played a swinging Cherokee Boogie and a first-class rendition of Don Santiago Jimenezs Ay Te Dejo En San Antonio. Perales has had some serious health problems. Before he left the Empire stage, Perales took the microphone and, with well-honed show business timing, announced he was cancer-free. During the final number, Bob Dylans Quinn the Eskimo (Mighty Quinn), everyone sang along with a little more gusto.
For openers: Guitarist, singer and songwriter Chuck Mead, co-founder of the country outfit BR549, and His Grassy Knoll Boys, one of the best trios going, opened with a tight, 40-minute, 14-song set that twanged with abandon. Mead and company worked the room perfectly, opening with One Long Saturday Night and hitting on all country cylinders through The Devil In Me, the BR549 hit Me and Opie (Down By the Duck Pond) and classic covers from the bands latest CD, Back at the Quonset Hut, including Settin the Woods on Fire, Girl on the Billboard and Honky Tonk Hardwood Floor. Nashville came to the Empire and made an impression.
Link:
PITTSBURGH--(BUSINESS WIRE)--
Andrew R. Watson, MD, MLitt, FACS, medical director for the Center for Connected Medicine, a global thought leader defining the transformation of health care, will moderate a breakfast panel opening this years mHealth Summit Dec. 3-5 in Washington, D.C. The session, sponsored by Healthcare IT News and mHIMSS.org, will consider physician reluctance to embrace mHealth, as well as explore both short- and long-term challenges and solutions.
Physician hesitation to adopt mobile technology runs contrary to consumers desire to conduct more and more of their lives via smartphone, tablet or similar device. Concerned about losing the personal connection with patients, many providers have been slow to implement emerging solutions. Ironically, this unwillingness may actually alienate tech-savvy individuals who prefer caregivers that can communicate in ways they consider convenient and comfortable.
The session, scheduled for 7:30-8:45 a.m. Monday, Dec. 3, preceding the summit's opening keynote, is titled mPowering the Physician in the Era of Patient-Directed Healthcare. Panelists include:
Panelists will address issues such as how to engage physicians in the mHealth conversation and how to best introduce mHealth technology into a practice. In addition, they will present best practices in mHealth technology that are producing reliable clinical outcomes for physicians. Other issues to be discussed include privacy and security concerns; patient accountability; reimbursement platforms; protocols for using approved devices; and the regulation and management of mobile apps.
The mHealth Summit is a great forum for discussing current perspectives and best practices for mHealth adoption, says Dr. Watson. I look forward to the opportunity to participate in this session, intended to shine a spotlight on the great value mHealth technology can provide. Candid discussion will help reassure physicians that, however daunting the transition may be, embracing mobility will benefit them and their patients.
ABOUT THE CENTER FOR CONNECTED MEDICINE
The Center for Connected Medicine is defining the transformation of health care by serving as a global thought leader. It is the worlds first collaborative health care executive briefing center dedicated to developing the blueprint for innovative patient-centered health through understanding new models of care and leveraging strategically integrated health information technology. Based in Pittsburgh, the Center opened its doors in September 2009 and is comprised of four founding partners: Alcatel-Lucent, IBM, UPMC and Verizon and eight strategic partners representing global leaders in health care. The Center draws executives and clinicians from around the world to explore the transformation of heath care. Visitors experience the possibilities of an interconnected health care system firsthand, with real clinical examples, and leave the Center with new insights and methods for reinventing their organizations, streamlining their processes and embracing the new paradigm in health care. To learn more about connected medicine, as well as the Centers vision and initiatives, please visit http://www.connectedmed.com.
Read the original:
Center for Connected Medicine Executive to Moderate Panel Session at mHealth Summit 2012
KUALA LUMPUR: The Dewan Negara on Monday passed the Traditional and Complementary Medicine Bill 2012 which requires all traditional medicine practitioners to register with the Council of Traditional and Complementary Medicine.
"The Bill does not allow individuals who only attend a short course (in the discipline) to use the title of doctor, for example Dr (H) for a practitioner of homeopathy," she said.
Rosnah said 13,811 practitioners of traditional and complementary medicine had registered with the ministry in the country so far.
On Islamic medicine or Rukyah, she said the Health Ministry had published a book "Garis Panduan dalam Perubatan Islam" (Guide to Islamic Medicine) which must be adhered to by the practitioners.
"Some 600 practitioners of Islamic medicine have registered with the ministry," she said.
Rosnah said eight local institutions of higher learning offered academic studies on traditional and complementary medicine.
"The courses include the Degree Programme for Traditional Chinese Medicine, Bachelor of Traditional Chinese Medicine and Bachelor of Homeopathy.
"The institutions include the Southern College in Skudai; Universiti Tuanku Abdul Rahman; Cyberjaya University College of Medical Sciences; Management and Science University (MSU) and the Melaka College of Complementary Medicine(MCCM)," she said.
The house will sit again Tuesday.
Read more:
SAN JOSE, Calif., Dec. 3, 2012 /PRNewswire/ --Ariosa Diagnostics today announced that the Harmony Prenatal Test was featured during a presentation at the Fetal Medicine Foundation's "Advances in Fetal Medicine" course on Dec. 1, 2012 in London. Professor Kypros Nicolaides, M.D., director of the Fetal Medicine Centre (http://www.fetalmedicine.com/fmc/) and the Harris Birthright Research Centre for Fetal Medicine (http://www.harrisbirthright.org/), highlighted the center's clinical experience with the Harmony test as well as how to implement non-invasive prenatal testing (NIPT) with cell-free DNA (cfDNA) analysis in routine clinical practice for a general screening population. The center is currently offering the Harmony test to all pregnant women with a singleton pregnancy at 10 weeks of gestational age or later. More than 700 physicians and international experts from 70 countries in fetal medicine attended the course.
(Logo: http://photos.prnewswire.com/prnh/20121203/NE22396LOGO)
"Cell-free DNA testing, such as that with the Harmony test, represents a brilliant new development and must be offered as a routine test," Nicolaides said. "Since introducing the Harmony test at the Fetal Medicine Centre, we have already seen the benefit of detecting cases of Down syndrome that would have been missed with conventional first-trimester combined screening. We have also avoided unnecessary invasive procedures that would otherwise have been performed due to false positive results from conventional screening."
The Harmony test analyzes cfDNA circulating in maternal blood and allows for a high level of accuracy in detecting fetal trisomies, such as trisomy 21, which causes Down syndrome. Nicolaides and his research team have produced four studies of the Harmony test (involving thousands of women) that have shown a greater than 99 percent detection rate for trisomy 21 and false positives of less than 0.1 percent.
The Fetal Medicine Centre became the first institution outside of North America to begin offering the Harmony test to patients in October 2012, and Nicolaides and his team are evaluating the clinical experiences of patients who undergo the testing and give birth. Ariosa plans to expand the availability of the Harmony test internationally. The Harmony test involves a single, standard blood draw performed as early as 10 weeks' gestation.
About The Fetal Medicine Foundation (FMF)
The FMF (www.fetalmedicine.com) is a registered charity in the United Kingdom that aims to improve the health of pregnant women and their babies through research and training in fetal medicine.
The main source of income to the charity is a private clinic, the Fetal Medicine Centre (http://www.fetalmedicine.com/fmc/), which donates all profits to the FMF. Dr. Kypros Nicolaides provides all services to FMC and FMF free of charge.
In the last 16 years, the FMF has supported research and training in fetal medicine through grants to doctors (370 doctors from 50 countries) working at King's College Hospital for the development of safer techniques for prenatal diagnosis of fetal abnormalities, intrauterine fetal surgery and for the prediction and prevention of miscarriage, stillbirth, premature birth, preeclampsia and abnormal fetal growth.
About Ariosa Diagnostics
Continue reading here:
SOUTH SAN FRANCISCO, CA--(Marketwire - Dec 3, 2012) - VistaGen Therapeutics, Inc. ( OTCBB : VSTA ), a biotechnology company applying stem cell technology for drug rescue, predictive toxicology and drug metabolism screening, has formalized its membership in the Toronto-based Centre for Commercialization of Regenerative Medicine's (CCRM) Industry Consortium.
"VistaGen's membership reflects our strong association with CCRM and its core programs and objectives, both directly and through our strategic relationships with Dr. Gordon Keller and the University Health Network (UHN).Our long-term sponsored research agreement with Dr. Keller, UHN and UHN's McEwen Centre for Regenerative Medicine offers both a solid foundation and unique opportunities for expanding the commercial applications of our Human Clinical Trials in a Test Tube platform by building multi-party collaborations with CCRM and members of its Industry Consortium," says Shawn Singh, VistaGen CEO. "These collaborations have the potential to transform medicine and accelerate significant advances in human health and wellness that stem cell technologies and regenerative medicine promise."
"Even before VistaGen joined CCRM's Industry Consortium it was active in the Toronto regenerative medicine community and advising us as we prepared to launch in 2011," explains Dr. Michael May, CEO of the Centre for Commercialization of Regenerative Medicine. "I'm confident that our relationship will grow stronger with VistaGen as a formal partner and I look forward to us working closely together on projects that will accelerate drug discovery and benefit patients."
CCRM is a not-for-profit, public-private consortium funded by the Government of Canada, six Ontario-based institutional partners and more than 20 companies representing the key sectors of the regenerative medicine industry. CCRM supports the development of foundational technologies that accelerate the commercialization of stem cell- and biomaterials-based products and therapies. Other members of CCRM's Industry Consortium include such leading global companies as Pfizer, GE Healthcare and Lonza.
The industry leaders that comprise the CCRM consortium benefit from proprietary access to certain licensing opportunities, academic rates on fee-for-service contracts at CCRM and opportunities to participate in large collaborative projects, among other advantages.VistaGen is especially well positioned through its existing relationships with key members.
Gordon Keller, Ph.D. is Director of the McEwen Centre for Regenerative Medicine at UHN. A CCRM partner, the McEwen Centre is a world-renowned centre for stem cell biology and regenerative medicine and a world-class stem cell research facility. He is also a Professor at the University of Toronto in the Department of Medical Biophysics and Senior Scientist of the Ontario Cancer Institute in Toronto.Dr. Keller's lab is one of the world leaders in successfully applying principles from the study of developmental biology of many animal systems to the differentiation of pluripotent stem cell systems, resulting in reproducible, high-yield production of human heart, liver, blood and vascular cells.The results and procedures developed in Dr. Keller's lab are often quoted and used by academic scientists worldwide.
UHN, a major landmark in Canada's healthcare system, is one of the world's largest research hospitals, with major research in transplantation, cardiology, neurosciences, oncology, surgical innovation, infectious diseases and genomic medicine. Providing care to the community for more than two centuries, UHN brings together the talent and resources needed to achieve global impact and provide exemplary patient care, research and education.
About VistaGen Therapeutics
VistaGen is a biotechnology company applying human pluripotent stem cell technology for drug rescue, predictive toxicology and drug metabolism screening. VistaGen's drug rescue activities combine its human pluripotent stem cell technology platform, Human Clinical Trials in a Test Tube, with modern medicinal chemistry to generate new chemical variants (Drug Rescue Variants) of once-promising small-molecule drug candidates. These are drug candidates discontinued by pharmaceutical companies, the U.S. National Institutes of Health (NIH) or university laboratories after substantial investment and development due to heart or liver toxicity or metabolism issues. VistaGen uses its pluripotent stem cell technology to generate early indications, or predictions, of how humans will ultimately respond to new drug candidates before they are ever tested in humans, bringing human biology to the front end of the drug development process.
Additionally, VistaGen's small molecule drug candidate, AV-101, is completing Phase 1 development for treatment of neuropathic pain. Neuropathic pain, a serious and chronic condition causing pain after an injury or disease of the peripheral or central nervous system, affects millions of people worldwide.To date, VistaGen has been awarded over $8.5 million from the NIH for development of AV-101.
See the original post here: